300 related articles for article (PubMed ID: 33220333)
1. PTEN deficiency facilitates the therapeutic vulnerability to proteasome inhibitor bortezomib in gallbladder cancer.
Jiang TY; Feng XF; Fang Z; Cui XW; Lin YK; Pan YF; Yang C; Ding ZW; Zhang YJ; Tan YX; Wang HY; Dong LW
Cancer Lett; 2021 Mar; 501():187-199. PubMed ID: 33220333
[TBL] [Abstract][Full Text] [Related]
2. PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma.
Jiang TY; Pan YF; Wan ZH; Lin YK; Zhu B; Yuan ZG; Ma YH; Shi YY; Zeng TM; Dong LW; Tan YX; Wang HY
Sci Transl Med; 2020 Sep; 12(562):. PubMed ID: 32967970
[TBL] [Abstract][Full Text] [Related]
3. Loss of BAP1 expression is associated with genetic mutation and can predict outcomes in gallbladder cancer.
Hirosawa T; Ishida M; Ishii K; Kanehara K; Kudo K; Ohnuma S; Kamei T; Motoi F; Naitoh T; Selaru FM; Unno M
PLoS One; 2018; 13(11):e0206643. PubMed ID: 30395583
[TBL] [Abstract][Full Text] [Related]
4. Oroxylin A Exerts Its Antitumor Effects in Human Gallbladder Cancer via Inhibition of the PTEN/PI3K/AKT Signaling Pathway.
Xuan L; Zhang J; Ji J; Hu J; Li F
Biol Pharm Bull; 2020; 43(10):1511-1518. PubMed ID: 32999161
[TBL] [Abstract][Full Text] [Related]
5. miR-223 increases gallbladder cancer cell sensitivity to docetaxel by downregulating STMN1.
Lu W; Hu Y; Ma Q; Zhou L; Jiang L; Li Z; Zhao S; Xu Y; Shi W; Li S; Liu Y
Oncotarget; 2016 Sep; 7(38):62364-62376. PubMed ID: 27577078
[TBL] [Abstract][Full Text] [Related]
6. Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma.
Chui MH; Doodnauth SA; Erdmann N; Tiedemann RE; Sircoulomb F; Drapkin R; Shaw P; Rottapel R
Cancer Res; 2019 Nov; 79(21):5536-5549. PubMed ID: 31530568
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib in previously treated phosphatase and tension homology-deficient patients with advanced intrahepatic cholangiocarcinoma: An open-label, prospective and single-centre phase II trial.
Zeng TM; Jiang TY; Yang G; Cheng Z; Lou C; Wei W; Tao CJ; Hu S; Wang H; Cui XW; Tan YX; Dong LW; Wang HY; Yuan ZG
Clin Transl Med; 2024 May; 14(5):e1675. PubMed ID: 38689424
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of tumor suppressor gene pten in early and advanced gallbladder cancer.
Roa I; de Toro G; Fernández F; Game A; Muñoz S; de Aretxabala X; Javle M
Diagn Pathol; 2015 Aug; 10():148. PubMed ID: 26294099
[TBL] [Abstract][Full Text] [Related]
9. p53 down-regulates phosphatase and tensin homologue deleted on chromosome 10 protein stability partially through caspase-mediated degradation in cells with proteasome dysfunction.
Tang Y; Eng C
Cancer Res; 2006 Jun; 66(12):6139-48. PubMed ID: 16778187
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNA SSTR5-AS1 facilitates gemcitabine resistance via stabilizing NONO in gallbladder carcinoma.
Xue Z; Yang B; Xu Q; Zhu X; Qin G
Biochem Biophys Res Commun; 2020 Feb; 522(4):952-959. PubMed ID: 31810606
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic Downregulation of PTEN in Gallbladder Cancer.
Tekcham DS; Gupta S; Shrivastav BR; Tiwari PK
J Gastrointest Cancer; 2017 Mar; 48(1):110-116. PubMed ID: 28124240
[TBL] [Abstract][Full Text] [Related]
12. Identification of MAP kinase pathways as therapeutic targets in gallbladder carcinoma using targeted parallel sequencing.
Li M; Chen L; Qu Y; Sui F; Yang Q; Ji M; Shi B; Chen M; Hou P
Oncotarget; 2017 May; 8(22):36319-36330. PubMed ID: 28422736
[TBL] [Abstract][Full Text] [Related]
13. DMBT1 suppresses progression of gallbladder carcinoma through PI3K/AKT signaling pathway by targeting PTEN.
Sheng S; Jiwen W; Dexiang Z; Bohao Z; Yueqi W; Han L; Xiaoling N; Tao S; Liu H
Biosci Biotechnol Biochem; 2019 Dec; 83(12):2257-2264. PubMed ID: 31411121
[TBL] [Abstract][Full Text] [Related]
14. HASPIN is involved in the progression of gallbladder carcinoma.
Zhu D; Gu X; Lin Z; Yu D; Wang J; Li L
Exp Cell Res; 2020 May; 390(2):111863. PubMed ID: 31987787
[TBL] [Abstract][Full Text] [Related]
15. Effects of PTEN gene alteration in patients with gallbladder cancer.
Ali A; Mishra PK; Sharma S; Arora A; Saluja SS
Cancer Genet; 2015 Dec; 208(12):587-94. PubMed ID: 26586294
[TBL] [Abstract][Full Text] [Related]
16. LDHA is a direct target of miR-30d-5p and contributes to aggressive progression of gallbladder carcinoma.
He Y; Chen X; Yu Y; Li J; Hu Q; Xue C; Chen J; Shen S; Luo Y; Ren F; Li C; Bao J; Yan J; Qian G; Ren Z; Sun R; Cui G
Mol Carcinog; 2018 Jun; 57(6):772-783. PubMed ID: 29569755
[TBL] [Abstract][Full Text] [Related]
17. Galectin-9: An anticancer molecule for gallbladder carcinoma.
Tadokoro T; Morishita A; Fujihara S; Iwama H; Niki T; Fujita K; Akashi E; Mimura S; Oura K; Sakamoto T; Nomura T; Tani J; Miyoshi H; Yoneyama H; Himoto T; Hirashima M; Masaki T
Int J Oncol; 2016 Mar; 48(3):1165-74. PubMed ID: 26797414
[TBL] [Abstract][Full Text] [Related]
18. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
19. Inhibition of ubiquitin proteasome function prevents monocrotaline-induced pulmonary arterial remodeling.
Zhu Y; Wu Y; Shi W; Wang J; Yan X; Wang Q; Liu Y; Yang L; Gao L; Li M
Life Sci; 2017 Mar; 173():36-42. PubMed ID: 28212825
[TBL] [Abstract][Full Text] [Related]
20. Prohibitin overexpression predicts poor prognosis and promotes cell proliferation and invasion through ERK pathway activation in gallbladder cancer.
Cao Y; Liang H; Zhang F; Luan Z; Zhao S; Wang XA; Liu S; Bao R; Shu Y; Ma Q; Zhu J; Liu Y
J Exp Clin Cancer Res; 2016 Apr; 35():68. PubMed ID: 27084680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
